The i-Lab competition offers equity-free funding up to €600K for proof-of-concept validated projects, matching the venture's pre-seed stage and French geography. The venture's AI/biotech drug resistance prediction technology aligns well with i-Lab's innovation focus, though the AUROC of 0.634 may need improvement to be competitive.